Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 6/20 | 0.47 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25398287 | 0.92 | MAPT (0.48) | MAPTRXFP1TP53DAGLAKDM4E | |
| SCHEMBL25400501 | 0.90 | RAB9A (0.47) | MAPTRXFP1TP53KDM4EAKR1B1 | |
| SCHEMBL25400080 | 0.85 | RAB9A (0.45) | MAPTRXFP1TP53DAGLAKDM4E | |
| SCHEMBL29437082 | 0.83 | LMNA (0.48) | MAPTTP53KDM4ELMNA | |
| SCHEMBL26554172 | 0.83 | LMNA (0.48) | MAPTTP53KDM4ELMNA | |
| SCHEMBL25401093 | 0.81 | DAGLA (0.43) | MAPTRXFP1TP53DAGLAKDM4E | |
| SCHEMBL25400913 | 0.79 | MAPT (0.47) | MAPTTP53LMNARAB9A | |
| SCHEMBL25401846 | 0.78 | HDAC6 (0.42) | MAPTRXFP1TP53DAGLAKDM4E | |
| SCHEMBL21814858 | 0.76 | MEN1 (0.56) | MAPTRXFP1DAGLAKDM4EAKR1B1 | |
| SCHEMBL25433686 | 0.76 | DAGLA (0.41) | MAPTRXFP1TP53DAGLAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331683-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-4211111-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | University of Virginia Patent Foundation (US) | 2023-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331683-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | SPNS2, SPCS2, SMN1; SMN2 | MAPT 30/4885RXFP1 2453/4885TP53 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.